Grade A · clinically studied3 peptides · 89 studies
GLP-1 metabolic framework (Semaglutide / Tirzepatide)
GLP-1 / GIP-GLP-1 framework reflecting some of the densest human data in the library.
This is a description, not a protocol to follow
Everything below is a summary of what people report doing and what the literature contains. Nothing here is medical advice.
What the evidence actually supports
Supported in animals
Animal-model studies indexed · 5
Cell and in-vitro studies indexed · 4
Reviews and uncategorised studies · 37
Not established
Any effect in humans · 43 human studies indexed
Any benefit from combining them · no combination study in our index
Human dose, route or duration · no PK study indexed
Protocol details
The combination of Semaglutide and Tirzepatide has not been studied together in published research. Evidence exists for each compound separately, but no trials have specifically examined their effects as a combined protocol.
Tirzepatide has been associated with lower odds of mechanical complications and infections compared to Semaglutide in patients undergoing major joint surgeries, although the clinical relevance of these findings should be interpreted cautiously [1]. Additionally, Tirzepatide has shown promise in preserving hematopoietic stem cell function and reducing inflammatory monocytes in obese mice, but these results require further investigation for applicability to human treatment [2]. In phase 3 trials, Tirzepatide was linked to significant weight loss, with a mean reduction of 20.9% [3]. However, it may also lead to reduced dietary intake and nutritional deficiencies that necessitate careful management [3].
Semaglutide has been studied for its effects on weight loss and side effects. In a real-world study, lower doses of compounded Semaglutide combined with behavioral management resulted in an average weight loss of 8.3% over 16 weeks [6]. Furthermore, lower doses were associated with a 34% reduction in the relative odds of gastrointestinal side effects compared to higher doses [7]. However, a meta-analysis found no conclusive evidence linking Semaglutide to increased or decreased suicidality, indicating that findings in this area are highly imprecise [5].
Overall, while individual studies provide insights into the effects of Semaglutide and Tirzepatide, the lack of research on their combined use means that no specific regimen or protocol has been established for this combination.
Sources
[1] Dual GIP/GLP-1 Receptor Agonist Versus Selective GLP-1 Receptor Agonist in Patients Undergoing Primary Total Knee or Hip Arthroplasty https://doi.org/10.21203/rs.3.rs-10744245/v1
[2] Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese mice https://doi.org/10.64898/2026.09.01.748392
[3] The GLP-1 Nutritional Paradox: A Structured Review with Novel Quantitative Frameworks for Sarcopenic Risk and Micronutrient Adequacy in GLP-1 Receptor Agonist Pharmacotherapy https://doi.org/10.21203/rs.3.rs-10929531/v1
[5] Semaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trials https://doi.org/10.21203/rs.3.rs-10976576/v1
[6] Weight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort study https://doi.org/10.64898/2026.09.08.26362528
[7] Side effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective study https://doi.org/10.64898/2026.09.08.26362532
Research & studies for this protocol
89 rows · showing 24Newest first
| Study | Compound | Source | Year |
|---|---|---|---|
| This study compared post-operative outcomes in patients undergoing primary total knee or hip arthroplasty who were prescribed tirzepatide versus semaglutide. The analysis involved a retrospective cohort of 8,797 patients with at least two prescriptions for either medication. At two years, tirzepatide was associated with lower odds of mechanical complications and periprosthetic joint infection compared to semaglutide. | Tirzepatide | biorxiv-preprint | — |
| This study measured the effects of tirzepatide on hematopoietic stem and progenitor cells (HSPCs) and inflammatory monocytes in obese mice. The findings indicated that tirzepatide preserved blood lineages and HSPC cycling compared to caloric restriction at equal weight loss. Not reported in abstract. | Tirzepatide | biorxiv-preprint | — |
| This review examines the impact of GLP-1 receptor agonists, specifically tirzepatide, on body weight and nutritional status. It reports mean body-weight reductions of 20.9% for tirzepatide and highlights a dietary intake reduction of 16–39%. Additionally, it discusses the associated risks of lean-body-mass loss and micronutrient deficiencies among users. | Tirzepatide | biorxiv-preprint | — |
| This study measured weight loss in adults initiating compounded injectable tirzepatide at doses below 2.5 mg weekly. The population included individuals with a baseline BMI ≥27 kg/m2. Results indicated weight loss at various follow-up windows, with no therapeutic claims made. | Tirzepatide | biorxiv-preprint | — |
| This study evaluated the association between semaglutide and suicidality in adults with overweight or obesity through a Bayesian meta-analysis of randomized trials. The primary outcome was completed suicide, with secondary outcomes including suicide attempts and suicidal ideation. The findings indicated no conclusive evidence of increased or decreased suicidality associated with semaglutide. | Semaglutide | biorxiv-preprint | — |
| This study evaluated the efficacy of a lower dose of compounded semaglutide in conjunction with a behavioral weight management program over 16 weeks. Participants included users of Noom Weight, Noom Microdose GLP-1 Rx Program, and Noom GLP-1 Rx Program. Weight loss results showed NMGP users lost 8.3% and NGP users lost 8.6% of their baseline weight. | Semaglutide | biorxiv-preprint | — |
| This study evaluated side effects of low versus standard doses of compounded semaglutide in a real-world setting over 16 weeks. It compared 7,682 users of the standard dose program to 2,877 users of the low dose program. The findings indicated lower odds of gastrointestinal and any side effects in the low dose group. | Semaglutide | biorxiv-preprint | — |
| The study developed a near-infrared (NIR) light-triggered platform for on-demand drug release in bone repair using a multifunctional biomimetic scaffold. The scaffold demonstrated dual-mode release behavior, good biocompatibility, and high antibacterial activity. The system showed accelerated drug release upon NIR irradiation and sustained release over 28 days without it. | Tirzepatide | europepmc | 2026 |
| This study investigated risk factors for progression from type 2 diabetes mellitus (T2DM) to end-stage renal disease (ESRD) using Mendelian randomization and logistic regression analysis. The T2DM GWAS dataset included 433,540 individuals, while a clinical cohort of 875 patients was analyzed, with 140 patients (16%) progressing to ESRD. Elevated body mass index (BMI) was identified as a causal risk factor, while higher hematocrit was protective. | Semaglutide | europepmc | 2026 |
| This study assessed the feasibility and acceptability of the ZIP approach for patient-centered decision-making in lung cancer screening and blood pressure management. It involved 23 patients and 10 primary care physicians in a single center study. The ZIP discussions took less than 4 minutes on average. | Semaglutide | europepmc | 2026 |
| Not reported in abstract. | Tirzepatide | PubMed | 2026 |
| This study evaluated oral health outcomes in 184,582 users of semaglutide or tirzepatide over a 12-month period. The research found that 8.69% of GLP-1 users developed at least one new oral-health condition, with dry mouth being the most frequent at 5.29%. Compared to matched users of other anti-diabetic therapies, GLP-1 users had a lower incidence of various oral-health conditions. | Semaglutide | biorxiv-preprint | 2026 |
| The study evaluated the effects of oral semaglutide on the islets of Langerhans in a type 2 diabetes mellitus rat model. Forty male albino wistar rats were used, with a dose of 0.23 mg/kg/day administered for 21 days. Significant changes in islet morphology and cellular integrity were observed in the semaglutide-treated group compared to the diabetic control group. | Semaglutide | biorxiv-preprint | 2026 |
| This study examined patient heterogeneity in routine biomarkers among cohorts treated with dapagliflozin and/or semaglutide. It found that a one-dimensional physiological reserve score was not supported, leading to a two-class solution based on biomarkers. The findings suggest that these biomarkers may better capture patient heterogeneity than a single score. | Semaglutide | biorxiv-preprint | 2026 |
| This study analyzed the reporting of impaired gastric emptying associated with five glucagon-like peptide-1 receptor agonists (GLP-1 RAs) using the FDA Adverse Event Reporting System. Semaglutide exhibited the highest proportional reporting ratio (PRR) of 88.7 based on 3,052 reports. The study does not assert causation but highlights the reporting trends for these substances. | Semaglutide | biorxiv-preprint | 2026 |
| This study analyzed the reporting of impaired gastric emptying associated with nine glucagon-like peptide-1 receptor agonists (GLP-1 RAs) using the FDA Adverse Event Reporting System. Semaglutide-based products exhibited the highest disproportionate reporting ratios. The findings indicate a need for further investigation into the clinical implications of these observations. | Semaglutide | biorxiv-preprint | 2026 |
| This study measures the feasibility and infrastructure of a double-blind, randomized trial of tirzepatide for Long COVID fatigue in a remote setting. The trial enrolled 1,058 participants over 73 days, utilizing a siteless design to reach severely affected patients. No treatment outcomes or efficacy results are reported in the abstract. | Tirzepatide | biorxiv-preprint | 2026 |
| This study analyzed weight trajectories in adults treated with semaglutide or tirzepatide, focusing on weight regain after initial loss. Among 58,618 patients, 8,389 (14.3%) regained ≥5 percentage points from their lowest body weight. The study also examined inflammatory markers and cardiovascular event rates associated with weight regain. | Semaglutide | biorxiv-preprint | 2026 |
| This review assessed the safety of turmeric and curcuminoids, particularly focusing on hepatotoxicity reports. The evaluation was conducted by the USP DSAEL EC following multiple hepatotoxicity cases associated with these supplements. The findings suggest that while hepatotoxicity has been observed in rodent studies, clinical trials have not reported significant organ toxicity. | Semaglutide | europepmc | 2026 |
| This study investigated experiences of hunger and eating habits in people with schizophrenia during semaglutide treatment. Eleven participants were interviewed 4 months to 1.5 years after treatment completion. The findings highlighted the impact of antipsychotics on hunger and the effects of semaglutide on these experiences. | Semaglutide | europepmc | 2026 |
| Not reported in abstract. | Semaglutide | PubMed | 2026 |
| Not reported in abstract. | Semaglutide | PubMed | 2026 |
| Not reported in abstract. | Semaglutide | PubMed | 2026 |
| Not reported in abstract. | Semaglutide | PubMed | 2026 |